Abstract
Purpose:
This study compared intraocular toxicity of intravitreally injected povidone-iodine (PI) and polyvinyl alcohol-iodine (PAI) in rabbits.
Methods:
In each rabbit, 0.1 mL of PI or PAI solution was injected intravitreally into one eye and saline was injected into the other. PI was tested at available iodine concentrations of 0.05%, 0.1%, 0.2%, and 0.5%, and PAI at 0.05%, 0.1%, and 0.2% (n = 6 each). Electroretinograms were recorded before injection and 1, 7, and 14 days after injection. Pathological examinations of eyeballs were performed on day 15.
Results:
Mean b-/a-wave ratios of the electroretinograms did not change in eyes injected with 0.05%, 0.1%, or 0.2% PI (PI-0.05, PI-0.1, and PI-0.2, respectively) or in eyes injected with 0.05% or 0.1% PAI (PAI-0.05 and PAI-0.1, respectively) compared to saline-injected eyes, but was transiently impaired on day 1 in PAI-0.2 eyes. Histopathologically, no retinal abnormalities were observed in PI-0.05, PAI-0.05, or PAI-0.1 eyes. One PI-0.1 eye first showed localized inflammatory cell infiltration in the inferior retinal region. Two PI-0.2 eyes and one PAI-0.2 eye had retinal degeneration and inflammatory cell infiltration. In the PI-0.5 group, extensive inflammatory cell infiltration was observed in six eyes and inferior retinal detachment in five eyes.
Conclusions:
PI and PAI have equivalent retinal toxicity profiles, and retinal toxicity first affects the inner retinal layer in the inferior region. The highest non-retinotoxic vitreous concentration is 0.0033% available iodine from intravitreal injection of PI or PAI containing 0.05% available iodine.
Translational Relevance:
Low concentrations of PI or PAI can be used to wash the ocular surface during surgery or intravitreal injection to prevent endophthalmitis.
The rabbits were anesthetized with intramuscular injection of 25 mg/kg ketamine and 2 mg/kg xylazine. Iodine preparation or physiological saline was injected into the vitreous using a 27-gauge needle inserted approximately 2 mm posterior to the limbus in the superior temporal quadrant. The PI product used was Isodine solution 10% (Mundipharma International Ltd., Cambridge, UK), and the PAI product was PA Iodo Ophthalmic and Eye Washing Solution (Nitten Pharmaceutical Co., Ltd., Nagoya, Japan). The PI product contains 1% available iodine, and the PAI product contains 0.2% available iodine. The two products were tested at equivalent available iodine concentrations. The PAI solutions tested contained 0.2% (neat solution; PAI-0.2 eyes), 0.1% (1:2 dilution; PAI-0.1 eyes), and 0.05% available iodine (1:4 dilution; PAI-0.05 eyes). For PI, an additional higher iodine concentration was tested. Thus, the PI solutions tested contained 0.5% (1:2 dilution; PI-0.5 eyes), 0.2% (1:5 dilution; PI-0.2 eyes), 0.1% (1:10 dilution; PI-0.1 eyes), and 0.05% available iodine (1:20 dilution; PI-0.05 eyes). PI and PAI were diluted with physiological saline. In each rabbit, 0.1 mL of saline was injected intravitreally into one eye (right eye), and 0.1 mL of test solution was injected into the contralateral eye (left eye).
Using a direct ophthalmoscope (Welch Allyn, Skaneateles Falls, NY, USA), the anterior and posterior segments of the rabbits’ eyes were examined under mydriasis with 0.5% tropicamide and 0.5% phenylephrine. All animals were examined using a hand-held slit lamp (Welch Allyn) and ophthalmoscope (Welch Allyn) before intravitreal injection, immediately after injection, and 1, 7, 14 (before dark adaptation), and 15 days after injection.
At day 15 after intravitreal injection, animals were given intravenous pentobarbital sodium (Somnopentyl; Kyoritsu Seiyaku Corp., Tokyo, Japan) and euthanized by exsanguination. The enucleated eyeballs were incised vertically at the temporal side and then immersed in 1% buffered formaldehyde with 2.5% glutaraldehyde. The next day, they were transferred to 10% buffered formalin. Tissues were paraffin-embedded, sectioned at 4 µm, and stained with hematoxylin and eosin (HE). Histological examinations of the eyeball including the retina, optic nerve, cornea, anterior chamber angle, and lens were performed using a light microscope.
The amplitudes and the implicit times of ERG were calculated as the ratio of the left to right eye of the same animal (iodine-injected/saline-injected). Statistical analyses were performed using GraphPad Prism 7 (Graph Pad Software, San Diego, CA, USA). Statistical comparisons of the amplitude ratio and implicit time ratio among four time periods (before injection and 1, 7, and 14 days after injection) were performed by Bonferroni multiple comparisons. P < 0.05 was considered statistically significant (multiplicity-adjusted P values). Comparison of the b-/a-wave ratio between eyes was performed by paired t-test, and P < 0.05 was considered statistically significant.
Physiological saline and iodine preparations (PI-0.05, PI-0.1, PI-0.2, PI-0.5, PAI-0.05, PAI-0.1, and PAI-0.2) were injected intravitreally into rabbits to evaluate the effects of the solutions on the retina. ERG recordings were performed before injection and 1, 7, and 14 days after injection. Histological examination was performed at day 15, after finishing the 14-day ERG follow-up.
The effects of intravitreal PAI injection on rabbit retina were compared with PI injection by ERG and pathology. We found that PI and PAI had equivalent retinal toxicity profiles, and retinal toxicity first affected the inner retinal layer in inferior region. We also demonstrated that the highest non-retinotoxic vitreous concentration was 0.0033% available iodine, when 0.1 mL of 0.05% PI or PAI was injected intravitreally.
PI was first developed in 1956
33 and is widely used not only in Japan but also worldwide. PI exhibits wide-spectrum microbicidal actions, is low cost, does not induce drug resistance, and has rapid microbicidal action.
8,11,18 In addition, the safe concentrations and toxicity for intraocular tissues have been studied in detail.
11,18 On the other hand, PAI was developed in 1959
34 and is widely used mainly in Japan.
35,36 PAI contains 2 mg of iodine per mL (0.2% available iodine), and the addition of the surfactant polyvinyl alcohol (80 mg/mL) reduces irritation to the eye.
Previous studies have used ERG and retinal tissue pathology to evaluate retinal damage as an indicator of intraocular toxicity. Several studies have examined the effects of intravitreal PI on retinal function and tissue in rabbits. Trost et al.
28 reported no effects on ERGs or retinal tissue following intravitreal injection 0.1 mL of PI with available iodine concentrations of 0.005%, 0.01%, 0.02%, and 0.04%. Kim et al.
29 showed that single intravitreal injection of 0.1 mL of PI with available iodine concentrations of 0.01 and 0.03% did not adversely affect ERGs and histologic examination. Whitacre et al.
27 injected 0.1 mL of PI with available iodine concentrations of 0.005%, 0.05%, and 0.5% intravitreally into rabbit eyes and found reduced ERG amplitudes and retinal tissue damage in 1 of 10 eyes at 0.05%. In this one eye, mild suppression (22%) of a- and b-waves of the ERG was seen one week after injection. Pathological examination of this eye revealed focal retinal edema and necrosis involving the visual streak and inferior retina. All four eyes injected with 0.5% developed temporary hypotony, iridocyclitis, and full thickness retinal necrosis. An immediate, profound (40%–80%) reduction of a- and b-waves was seen in all eyes. One day after injection, there was edema in the nerve fibers, ganglion cells, and inner plexiform layers of the retina. At 7 and 28 days, full-thickness necrosis of the sensory retina was observed.
In the present study, ERG and pathological findings indicate that the highest vitreous concentration without retinal toxicity was due to intravitreal injection of 0.1 mL of 0.05% PI or 0.1% PAI. This amount is noteworthy, because when injected into the rabbit vitreous that has a volume of 1.5 mL, 0.1 mL of 0.05% available iodine concentration will be diluted to 0.0033% (
Fig. 5). Brozou et al.
37 reported that intravitreal injection of PI with 0.01% available iodine (0.00067% in rabbit vitreous) did not inhibit bacterial endophthalmitis, whereas PI with 0.02% available iodine (0.0013% in rabbit vitreous) was likely to inhibit bacterial endophthalmitis. From their findings and the results of this study, the effective vitreous concentration range for endophthalmitis without retinal toxicity can be calculated as 0.0013% to 0.0033%. This supports the clinical report of Nakashizuka et al.,
38,39 who treated endophthalmitis with intravitreal injections of 0.1 mL of PI with 0.125% available iodine (0.0025% in 5 mL of human vitreous) followed by vitrectomy using 0.0025% PI in BSS PLUS (Alcon, Ft. Worth, TX, USA). For the treatment of endophthalmitis, intravitreal injection with 0.125% PI is a non-retinotoxic concentration; however, the PI added to the intraocular cleansing solution makes contact with intraocular tissues already damaged by endophthalmitis. Therefore, the lowest concentration of 0.0013% PI should be selected.
40
If iodine can be added to the infusion fluid used in cataract and vitreous surgeries, it will be useful in preventing endophthalmitis. In this study, the initial retinal toxicity was observed with PI or PAI containing 0.1% available iodine (0.0067% in rabbit vitreous). Therefore, a 1/10 concentration, or 0.01% (0.00067% in rabbit vitreous), may be suitable for prevention of endophthalmitis.
41,42
In previous studies, washing the ocular surface with a 0.025% available iodine concentration of PI (0.25% iodine concentration) during surgery has prevented the normal flora on the ocular surface from entering the eye.
9,10 In the clinical setting, when 0.1 mL of PI or PAI containing 0.025% available iodine is introduced into human vitreous (0.0005% in 5 mL of human vitreous), the concentration is not considered to be retinotoxic.
In this study, no retinal abnormalities were observed in PAI-0.05, PI-0.05, and PAI-0.1 eyes. Among six PI-0.1 eyes, one eye showed localized inflammatory cell infiltration in the region inferior to the central retina. These results suggest that early retinal damage due to iodine occurs in the region inferior to the central retina. In PAI-0.2 and PI-0.2 eyes, an iodine concentration that has not been researched previously, inflammatory cell infiltration in the retina and destruction of retinal layer structure were observed in the region inferior to the central retina extending to the peripheral retina. In PI-0.5 eyes, extensive inflammatory cell infiltration and retinal detachment were observed in the region inferior to the optic disc.
Ocular tissue specimens are usually studied histopathologically by preparing horizontal sections of the eyeball. In this study, however, vertical sections were made to view the regions around of the central retina. The injected PAI or PI was clearly visible following injection as a brown cloud concentrated in the posterior vitreous, which spread over the entire posterior pole within several minutes. Kim et al.
29 reported that the half-life of PI in the vitreous of rabbit eyes was approximately 3 hours; however, vitreous body of a healthy rabbit is highly viscous, and the rabbit always has the 12 o'clock position of the eyeball positioned upward. Therefore, the presence of relatively high concentration of iodine near the inferior region of the eye could have led to the development of local damage. In order to observe the retinal damage caused by intravitreal injection of the drug, it is important to observe the eyeball by vertical section centering on the optic disc.
Next, we analyzed the ERG findings in detail. The mean b-/a-wave ratio ERGs did not change in PI-0.05, PI-0.1, PI-0.2, PAI-0.05, or PAI-0.1 eyes compared to saline-injected eyes. Although PAI-0.2 eyes showed transient mild but significant reduction on day 1, PI-0.2 eyes showed transient mild reduction that was not statistically significant. These results showed that 0.2% injection of PI or PAI caused transient mild electrophysiological dysfunction to the middle retinal layers. In contrast, the b-/a-wave ratio in PI-0.5 eyes was markedly and significantly reduced compared to saline-injected eyes at 1 day after injection, due to significant decreases in b-wave amplitudes but no change in a-waves. Thereafter, the b-/a-wave ratio increased with time to levels similar to those in saline-injected eyes. This was not due to improvement of function in the middle layers but instead was caused by significant decrease of function in the outer layers together with continued decline in the middle layers. Iodine injected into the vitreous is thought to affect the inner layer of the retina first and subsequently the outer layer of the retina. Because we performed pathological examinations on the 15th day after iodine injection, we assumed that the results reflected the end stage of the effects of iodine-induced retinal toxicity. Thus, we were not able to follow the changes over time. Moreover, there are no reports of iodine-induced retinal pathology observed over time. Because optic nerve head atrophy was observed in PI-0.5 eyes at day 15, further histopathological study is needed to examine the initial lesion and subsequent transition of retinal toxicity over time after intravitreal injection of iodine. In addition the visual evoked potential would be useful to detect initial alteration of optic nerve function. Using techniques such as optical coherence tomography, it may be possible to observe the temporal changes in the layer structure of the entire retina.
Technical assistance for animal experiments was provided by Nitten Pharmaceutical Co.
Disclosure: H. Shimada, None; K. Kato, Nitten Pharmaceutical Co. (E); K. Ishida, Nitten Pharmaceutical Co. (E); T. Yamaguchi, Nitten Pharmaceutical Co. (E); K. Shinoda, None